However, mounting preclinical, epidemiologic and early phase clinical trial data support the further exploration of these drugs in diseases as varied as breast and salivary gland cancers, and it is likely that in the ensuing decade next generation AR-directed drugs will extend their reach beyond prostate cancer. The gene discussed is AR; the disease is salivary gland cancer.